NCT01365065View on ClinicalTrials.gov

Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2018

Conditions
HIV Positive
Interventions
DRUG

Vorinostat

Vorinostat 400mg (4 x 100mg) orally daily for 14 days

Trial Locations (1)

3004

The Alfred Hospital - Infectious Diseases Unit, Melbourne

Sponsors

Lead Sponsor

Bayside Health
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Bayside Health

OTHER_GOV